Tags

Type your tag names separated by a space and hit enter

Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk.
Am J Epidemiol 2007; 165(10):1187-98AJ

Abstract

It is unclear whether breast cancer risk varies by age and menopausal status in relation to use of hormonal birth control (HBC) and hormone replacement therapy (HRT), taken singly or cumulatively. The authors utilized data from 1,478 cases and 1,493 controls aged 20-98 years with known menopausal status, who had participated in a population-based, case-control study conducted on Long Island during 1996-1997. Exogenous hormone use over the lifecourse was assessed by use of memory aids. The authors examined associations among women in these subgroups: premenopausal (n = 968), postmenopausal <65 years (n = 1,045), and postmenopausal > or = 65 years (n = 958). Among premenopausal women, risk was increased for ever use of HBC (odds ratio (OR) = 1.37, 95% confidence interval (CI): 1.04, 1.81) or HRT (OR = 1.81, 95% CI: 1.17, 2.81) and was pronounced among women reporting use of both HBC and HRT (OR = 2.59, 95% CI: 1.50, 4.46), long-term HRT use (OR = 3.93, 95% CI: 1.43, 10.84), or estrogen-plus-progestin therapy (OR = 3.51, 95% CI: 1.45, 8.49). There was no effect of ever HBC use among postmenopausal women aged less than 65 years, but risk was modestly elevated for more than 5 years of HRT use (OR = 1.41, 95% CI: 1.00, 1.99). Among postmenopausal women aged 65 years or more, odds ratios for HBC or HRT use were around the null. These results emphasize that timing of exogenous hormone use is important. Women who used these hormones before menopause had elevated risks, but the harmful effects began to decline with age after menopause.

Authors+Show Affiliations

Department of Epidemiology, University of North Carolina School of Public Health, Chapel Hill, NC, USA. sumitra.y.shantakumar@gsk.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

17337757

Citation

Shantakumar, Sumitra, et al. "Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk." American Journal of Epidemiology, vol. 165, no. 10, 2007, pp. 1187-98.
Shantakumar S, Terry MB, Paykin A, et al. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol. 2007;165(10):1187-98.
Shantakumar, S., Terry, M. B., Paykin, A., Teitelbaum, S. L., Britton, J. A., Moorman, P. G., ... Gammon, M. D. (2007). Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. American Journal of Epidemiology, 165(10), pp. 1187-98.
Shantakumar S, et al. Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk. Am J Epidemiol. 2007 May 15;165(10):1187-98. PubMed PMID: 17337757.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. AU - Shantakumar,Sumitra, AU - Terry,Mary Beth, AU - Paykin,Andrea, AU - Teitelbaum,Susan L, AU - Britton,Julie A, AU - Moorman,Patricia G, AU - Kritchevsky,Stephen B, AU - Neugut,Alfred I, AU - Gammon,Marilie D, Y1 - 2007/03/03/ PY - 2007/3/6/pubmed PY - 2007/7/11/medline PY - 2007/3/6/entrez SP - 1187 EP - 98 JF - American journal of epidemiology JO - Am. J. Epidemiol. VL - 165 IS - 10 N2 - It is unclear whether breast cancer risk varies by age and menopausal status in relation to use of hormonal birth control (HBC) and hormone replacement therapy (HRT), taken singly or cumulatively. The authors utilized data from 1,478 cases and 1,493 controls aged 20-98 years with known menopausal status, who had participated in a population-based, case-control study conducted on Long Island during 1996-1997. Exogenous hormone use over the lifecourse was assessed by use of memory aids. The authors examined associations among women in these subgroups: premenopausal (n = 968), postmenopausal <65 years (n = 1,045), and postmenopausal > or = 65 years (n = 958). Among premenopausal women, risk was increased for ever use of HBC (odds ratio (OR) = 1.37, 95% confidence interval (CI): 1.04, 1.81) or HRT (OR = 1.81, 95% CI: 1.17, 2.81) and was pronounced among women reporting use of both HBC and HRT (OR = 2.59, 95% CI: 1.50, 4.46), long-term HRT use (OR = 3.93, 95% CI: 1.43, 10.84), or estrogen-plus-progestin therapy (OR = 3.51, 95% CI: 1.45, 8.49). There was no effect of ever HBC use among postmenopausal women aged less than 65 years, but risk was modestly elevated for more than 5 years of HRT use (OR = 1.41, 95% CI: 1.00, 1.99). Among postmenopausal women aged 65 years or more, odds ratios for HBC or HRT use were around the null. These results emphasize that timing of exogenous hormone use is important. Women who used these hormones before menopause had elevated risks, but the harmful effects began to decline with age after menopause. SN - 0002-9262 UR - https://www.unboundmedicine.com/medline/citation/17337757/Age_and_menopausal_effects_of_hormonal_birth_control_and_hormone_replacement_therapy_in_relation_to_breast_cancer_risk_ L2 - https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwm006 DB - PRIME DP - Unbound Medicine ER -